Drugs / ApoCell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00524784 | Jun 2009 → Dec 2012 | acute graft versus host disease, hematopoietic and lymphoid cell neoplasm | Hadassah Medical Organization | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ApoCell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00524784 ↗ |
| Modality | Cell therapy | “The ApoCell product is composed of HLA-matched donor mononuclear enriched leukocytes in the form of liquid suspension” NCT00524784 ↗ |
| Route | Intravenous | “will be injected intravenously to the patient 24 hours prior to HSCT” NCT00524784 ↗ |